(-0.07%) 5 465.59 points
(0.09%) 39 146 points
(0.13%) 17 740 points
(-0.05%) $80.79
(-5.04%) $2.62
(-0.86%) $2 310.70
(-0.29%) $28.79
(3.19%) $1 017.90
(0.34%) $0.936
(0.73%) $10.68
(0.52%) $0.792
(-0.27%) $87.26
7.39% $ 1.235
Live Chart Being Loaded With Signals
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases...
Stats | |
---|---|
Volumen de hoy | 368 056 |
Volumen promedio | 193 348 |
Capitalización de mercado | 51.31M |
EPS | $-0.460 ( Q1 | 2024-05-09 ) |
Próxima fecha de ganancias | ( $-0.360 ) 2024-08-08 |
Last Dividend | $0.361 ( 2023-03-08 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.100 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00400 (0.32%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-17 | Morris Richard Steven | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Klichinsky Michael | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Kelly Steven | Buy | 125 000 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 38 700 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 0 |
INSIDER POWER |
---|
100.00 |
Last 7 transactions |
Buy: 1 112 700 | Sell: 0 |
Volumen Correlación
Carisma Therapeutics, Correlación
10 Correlaciones Más Positivas | |
---|---|
OZEM | 1 |
BNZI | 0.962 |
LUXH | 0.96 |
AAME | 0.942 |
CHUY | 0.936 |
FRGT | 0.934 |
AMPL | 0.933 |
HPKEW | 0.933 |
DYFI | 0.932 |
AEON | 0.931 |
10 Correlaciones Más Negativas | |
---|---|
JAJWX | -0.955 |
DTI | -0.944 |
ATMV | -0.94 |
CNRLX | -0.94 |
NEOV | -0.928 |
OCMAX | -0.928 |
IROH | -0.925 |
FORL | -0.922 |
QTTB | -0.92 |
ISRL | -0.919 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Carisma Therapeutics, Correlación - Moneda/Commodity
Carisma Therapeutics, Finanzas
Annual | 2023 |
Ingresos: | $14.92M |
Beneficio Bruto: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2023 |
Ingresos: | $14.92M |
Beneficio Bruto: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2022 |
Ingresos: | $9.83M |
Beneficio Bruto: | $3.74M (38.07 %) |
EPS: | $-575.42 |
Financial Reports:
No articles found.
Carisma Therapeutics, Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.361 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.361 | 2023-03-08 |
Last Dividend | $0.361 | 2023-03-08 |
Next Dividend | $0 | N/A |
Payout Date | 2023-03-08 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.361 | -- |
Avg. Dividend % Per Year | 0.94% | -- |
Score | 0.39 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.361 | 2.82% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
08 Mar 2023 | $0.361 | 03 Feb 2023 | 07 Mar 2023 | 08 Mar 2023 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -5.39 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.101 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.16 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.42 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.30 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.102 | -1.500 | 8.31 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -103.61 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.968 | -1.935 | [0 - 20] |
debtEquityRatioTTM | 0.688 | -1.500 | 7.25 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.656 | 1.000 | 2.40 | 2.40 | [0.2 - 0.8] |
operatingProfitMarginTTM | -5.66 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -10.44 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.204 | 0.800 | -1.972 | -1.577 | [0.5 - 2] |
Total Score | -1.801 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.580 | 1.000 | -0.160 | 0 | [1 - 100] |
returnOnEquityTTM | -2.16 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.645 | -1.935 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0261 | 1.500 | -3.51 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -5.19 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.80 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Carisma Therapeutics,
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico